Q-omics provides the consensus-scored GPR25 profile across patient tissues and cancer cell-line models. GPR25 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, GPR25 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, GPR25 RNA expression shows 10,624 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, KIRC, and TGCT as cancer lineages where GPR25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR25 survival associations across molecular data types. GPR25 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR25 RNA expression–survival associations across cancer types. High GPR25 expression shows unfavorable associations in UVM and KIRC, but favorable associations in BLCA, SKCM, HNSC and UCEC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for GPR25 RNA expression.
This table summarizes GPR25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GPR25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR25 shows higher tumor expression in KIRC, KIRP, KICH and LIHC. The KIRC box plot shows higher GPR25 RNA expression in tumor versus normal tissue (log2 FC = +0.223, t-test p < 0.001).
This table shows molecular features associated with GPR25 in patient tissues and cancer cell lines. In patient samples, GPR25 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR25 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SKIN.
